Nippon Chemiphar Co., Ltd. (JP:4539)
:4539
Want to see JP:4539 full AI Analyst Report?
Top Page
Nippon Chemiphar Co., Ltd.
(4539)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥1,687.00
▲(6.44% Upside)
Action:Reiterated
Date:05/17/26
The score is held back primarily by inconsistent profitability and persistently weak/free cash flow generation despite the strong revenue rebound. Technical indicators are broadly neutral with a slight bearish tilt, while valuation is a supportive factor due to the moderate P/E and ~3% dividend yield.
Positive Factors
Stable generics prescription business
A core focus on prescription generics and branded ethical drugs provides a durable, volume-driven revenue base under Japan’s reimbursement framework. In-house or contracted manufacturing and established distribution channels support steady supply and predictable institutional demand over months.
Negative Factors
Persistent negative free cash flow
Recurring negative free cash flow constrains the company’s ability to self-fund R&D, capex, and dividends, forcing reliance on external financing. Over a multi-month horizon this limits strategic flexibility, raises financing risk, and weakens the buffer against operational shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable generics prescription business
A core focus on prescription generics and branded ethical drugs provides a durable, volume-driven revenue base under Japan’s reimbursement framework. In-house or contracted manufacturing and established distribution channels support steady supply and predictable institutional demand over months.
Read all positive factors
Nippon Chemiphar Co., Ltd. (4539) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.88B
Dividend Yield3.21%
Average Volume (3M)2.30K
Price to Earnings (P/E)29.6
Beta (1Y)0.25
Revenue Growth1.60%
EPS Growth-32.76%
CountryJP
Employees887
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)109.50
Shares Outstanding4,261,420
10 Day Avg. Volume1,680
30 Day Avg. Volume2,300
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)0.33
Price to Sales (P/S)0.19
P/FCF Ratio-27.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nippon Chemiphar Co., Ltd. Business Overview & Revenue Model
Company Description
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic...
How the Company Makes Money
Nippon Chemiphar makes money primarily by selling pharmaceutical products in Japan. Its core revenue stream comes from prescription drug sales, with a meaningful portion derived from generic medicines (earning revenue based on volume sold to medic...
Nippon Chemiphar Co., Ltd. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
56
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.82B | 33.09B | 32.57B | 30.75B | 31.56B | 32.51B |
| Gross Profit | 8.93B | 8.40B | 8.75B | 7.74B | 8.19B | 9.07B |
| EBITDA | 2.01B | 1.74B | 1.83B | 1.40B | 2.10B | 2.68B |
| Net Income | 395.00M | 198.00M | 294.00M | -180.00M | 339.00M | 700.00M |
Balance Sheet | ||||||
| Total Assets | 52.68B | 49.98B | 49.85B | 49.55B | 48.57B | 49.45B |
| Cash, Cash Equivalents and Short-Term Investments | 9.69B | 5.34B | 7.02B | 9.20B | 10.53B | 11.64B |
| Total Debt | 19.02B | 16.58B | 18.06B | 16.98B | 15.23B | 14.79B |
| Total Liabilities | 33.76B | 30.46B | 30.68B | 31.08B | 30.03B | 30.95B |
| Stockholders Equity | 18.92B | 19.51B | 19.17B | 18.46B | 18.53B | 18.50B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -231.00M | -1.86B | -2.34B | -1.93B | 1.07B |
| Operating Cash Flow | 0.00 | 620.00M | -265.00M | 296.00M | -916.00M | 1.80B |
| Investing Cash Flow | 0.00 | -661.00M | -1.66B | -3.14B | -394.00M | 35.00M |
| Financing Cash Flow | 0.00 | -1.67B | -305.00M | 1.45B | 144.00M | -793.00M |
Nippon Chemiphar Co., Ltd. Technical Analysis
Negative
1585.00
Price Trends
1682.11
Negative
1672.71
Negative
1602.58
Positive
Market Momentum
-17.46
Positive
43.53
Neutral
25.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4539, the sentiment is Negative. The current price of 1585 is below the 20-day moving average (MA) of 1647.95, below the 50-day MA of 1682.11, and below the 200-day MA of 1602.58, indicating a neutral trend. The MACD of -17.46 indicates Positive momentum. The RSI at 43.53 is Neutral, neither overbought nor oversold. The STOCH value of 25.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4539.
Nippon Chemiphar Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥12.47B | 23.34 | ― | ― | 1.62% | -25.43% | |
63 Neutral | ¥8.90B | 14.24 | ― | 2.55% | -0.61% | 14.60% | |
63 Neutral | ¥32.89B | 11.24 | ― | 2.75% | 3.94% | 40.63% | |
53 Neutral | ¥9.34B | 41.09 | ― | 1.06% | 27.18% | 252.59% | |
52 Neutral | ¥17.57B | 8.54 | ― | 3.71% | 2.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥5.88B | 29.61 | ― | 3.21% | 1.60% | -32.76% |
* Healthcare Sector Average
JP:4539
Nippon Chemiphar Co., Ltd.
1,628.00
195.73
13.67%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
269.00
-32.46
-10.77%
JP:4524
Morishita Jintan Co., Ltd.
2,183.00
126.01
6.13%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,003.00
-46.47
-2.27%
JP:4574
Taiko Pharmaceutical Co., Ltd.
249.00
-3.00
-1.19%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,140.00
187.00
19.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.